


What science can do

AstraZeneca Pharma India Limited

Annual Report 2015-16



AstraZeneca

Welcome to AstraZeneca Pharma India Limited Annual Report 2015-2016

At AstraZeneca, each and every one of us is bold in the belief that science should be at the centre of everything we do.

Science compels us to push the boundaries of what is possible. We trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease.

Our main therapy areas:



Respiratory, Inflammation and Autoimmunity

We have pushed the boundaries of science in respiratory disease for 40 years



Cardiovascular and Metabolic diseases

We take an integrated patient approach to reduce cardiovascular morbidity and mortality



Oncology

We are committed to advancing the science of oncology

Our values are the point of reference for our decision-making and support the creation of a strong AstraZeneca culture.



**We follow
the science**



**We put
patients first**



**We play
to win**



**We do the
right thing**



**We are
entrepreneurial**



> Cambridge, UK



> Gaithersburg, Maryland US



> Gothenburg, Sweden

Globally we are increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres.



We have a state-of-the-art, oral solid dosage manufacturing facility located in Bangalore, India.



Since 2010, AstraZenca is committed to positively impact the health of adolescents in marginalised communities in Delhi through its Young Health Programme.



We are committed to provide additional support to help patients. We have patient assistance programs in respiratory, cardiovascular and oncology in India.

Contents

10	Notice
22	Directors' Report
41	Management Discussion & Analysis Report
47	Report on Corporate Governance
66	Auditors' Report
74	Balance Sheet
75	Statement of Profit and Loss
76	Cash Flow Statement
78	Notes to the Financial Statements
116	Ten Year Summary



AstraZeneca- Board of Directors



D E Udwadia
Chairman



K S Shah




Narayan K Seshadri



Sanjay Murdeshwar
Managing Director



Ian Brimicombe



Claire-Marie O'Grady

AstraZeneca Pharma India Limited

Board of Directors

Mr. D. E. Udawadia, Chairman
Mr. K. S. Shah
Mr. Narayan K Seshadri
Mr. Ian Brimicombe
Mr. Sanjay Murdeshwar, Managing Director
Ms. Claire-Marie O'Grady (from November 6, 2015)
Mr. Justin Ooi (upto January 11, 2016)
Ms. Rebekah Martin (upto November 6, 2015)

Auditors

BSR & Co. LLP, Bangalore

Legal Advisors

Udwadia & Co., Mumbai

Bankers

The Hongkong and Shanghai
Banking Corporation Limited

Corporate and Registered Office

Block N1, 12th Floor, Manyata Embassy
Business Park, Rachenahalli, Outer Ring
Road, Bangalore 560045

Factory

12th Mile on Bellary Road
Kattigenahalli Village, Yelahanka
Bangalore 560 063

Sales Outlets

Ahmedabad, Bangalore, Chennai, Cuttack,
Dehradun, Delhi*, Guwahati, Hyderabad,
Indore, Jaipur, Kochi, Kolkata, Lucknow,
Mumbai, Patna, Ranchi, Chandigarh,
Panchkula and Zirakhpur

*Company outlets (only Delhi)

Committees of Directors

Audit Committee

Mr. K. S. Shah, Chairman
Mr. D. E. Udawadia
Ms. Claire-Marie O'Grady

Nomination & Remuneration Committee

Mr. Narayan K Seshadri, Chairman
Mr. D. E. Udawadia
Mr. K. S. Shah
Mr. Ian Brimicombe

Stakeholders' Relationship Committee

Mr. K. S. Shah, Chairman
Mr. Sanjay Murdeshwar

Corporate Social Responsibility Committee

Mr. Ian Brimicombe, Chairman
Mr. D. E. Udawadia
Mr. Sanjay Murdeshwar

Chief Financial Officer

Mr. Rajesh Marwaha

Legal Counsel & Company Secretary

Mr. Anantha Murthy N

Annual General Meeting
at 3.00 p.m. on Thursday, August 11, 2016
at 'The Mysore Hall', ITC Gardenia, No.1,
Residency Road, Bangalore - 560025

AstraZeneca Pharma India Limited

Registered Office: Block N1, 12th Floor, Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road, Bangalore - 560045

CIN: L24231KA1979PLC003563, Web: www.astrazeneca.com/india

Email: comp.secy@astrazeneca.com, Tel: +91 80 67748000, Fax: +91 80 67748557

NOTICE

NOTICE is hereby given that the 37th Annual General Meeting of the Members of AstraZeneca Pharma India Limited will be held on **Thursday, August 11, 2016 at 3.00 p.m. at 'The Mysore Hall', ITC Gardenia, No.1, Residency Road, Bangalore - 560025**, to transact the following business:

ORDINARY BUSINESS

1. To receive, consider and adopt the financial statements viz., the Audited Balance Sheet as at March 31, 2016, the Audited Profit & Loss Account and the Cash Flow Statement of the Company and Explanatory Note annexed thereto or forming part of the above documents, for the financial year ended on that date and the Reports of the Board of Directors and Auditors thereon.
2. To appoint a Director in place of Mr. Sanjay Murdeshwar (holding DIN 01481811) who retires by rotation, and being eligible, offers himself for re-appointment.
3. To appoint M/s. Price Waterhouse & Co Chartered Accountants LLP (Firm Registration No. 304026E/E-300009), as Statutory Auditors of the Company in place of M/s. BSR & Co. LLP, the retiring Statutory Auditors, to hold office for a period of 5 years from the conclusion of this 37th Annual General Meeting, until the conclusion of 42nd Annual General Meeting, subject to ratification at every Annual General Meeting and to authorize the Board of Directors to fix their remuneration.

SPECIAL BUSINESS

4. To consider and if thought fit, to convey assent or dissent to the following Ordinary Resolution:

RESOLVED THAT pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with the Companies (Audit and Auditors) Rules, 2014, as amended to date, payment of remuneration of ₹ 1,50,000/- (Rupees one lac fifty thousand only) plus applicable service tax and reimbursement of out-of-pocket expenses, at actuals, to M/s. Rao, Murthy & Associates, Cost Accountants, Bangalore, (Firm Registration No.000065), appointed by the Board as Cost Auditors of the Company for conducting the cost audit of the accounts for the financial year ending March 31, 2017, be and is hereby confirmed, approved and ratified.

5. To consider and if thought fit, to convey assent or dissent to the following Ordinary Resolution:

RESOLVED THAT subject to the provisions of Regulation 23 (4) of Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 ('the Listing Regulations'), as amended to date, approval of the Members be and is hereby granted to the following Material Related Party Transactions entered into by the Company with AstraZeneca UK Limited (AZ UK), a Related Party as defined in Section 2(76) of the Act and in the Listing Regulations, during the financial year 2015-16:

(₹ in Crores)

Sl. No.	Nature of Material Related Party Transactions	Transactions Value (FY 2015-16)
1.	Purchase of raw materials and traded goods by the Company from AZ UK	102.07
2.	Reimbursement by AZ UK to the Company of the cost of employees deputed by the Company outside India	1.54
3.	Reimbursement by the Company to AZ UK, the cost related to overseas employees deputed in India	0.42
Total		104.03